Burney Co. Cuts Stock Holdings in Lantheus Holdings, Inc. $LNTH

Burney Co. trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,675 shares of the medical equipment provider’s stock after selling 1,639 shares during the quarter. Burney Co.’s holdings in Lantheus were worth $383,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LNTH. TD Asset Management Inc increased its holdings in shares of Lantheus by 1,028.0% during the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock valued at $66,623,000 after purchasing an additional 622,100 shares in the last quarter. Nuveen LLC purchased a new position in shares of Lantheus during the 1st quarter valued at approximately $55,941,000. Epoch Investment Partners Inc. purchased a new position in shares of Lantheus during the 1st quarter valued at approximately $35,548,000. Mackenzie Financial Corp increased its holdings in shares of Lantheus by 129.2% during the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider’s stock valued at $48,550,000 after purchasing an additional 280,381 shares in the last quarter. Finally, Nitorum Capital L.P. purchased a new position in shares of Lantheus during the 1st quarter valued at approximately $23,261,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,812,000 shares of company stock valued at $382,427,380. Corporate insiders own 1.50% of the company’s stock.

Lantheus Trading Down 0.8%

Shares of Lantheus stock opened at $57.23 on Thursday. The stock has a market cap of $3.89 billion, a P/E ratio of 15.22 and a beta of 0.04. The stock’s 50 day simple moving average is $54.20 and its 200-day simple moving average is $69.17. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The business had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings downgraded Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. William Blair reissued a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Mizuho reduced their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, TD Cowen reduced their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $74.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.